文献速递慢性肾脏病水电解质与酸碱血液净化与透析

血清钾与4-5期慢性肾脏病老年人死亡或肾脏替代治疗风险:八年随访

Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up.
PubMed 文献 · Am J Kidney Dis · 2023-05-12

本研究为前瞻性观察性队列研究,纳入欧洲EQUAL研究中1714例65岁及以上、首次估算肾小球滤过率低于20mL/min/1.73m2的4-5期慢性肾脏病患者,随访8年。分析显示血清钾与死亡或肾脏替代治疗启动呈U形关系,风险最低点约在血钾4.9mmol/L,低钾和高钾均与风险增加相关。

要点

  • 在4-5期慢性肾脏病老年人中,血清钾与死亡或肾脏替代治疗启动呈U形关系。
  • 风险最低点出现在血清钾约4.9mmol/L。
  • 低钾和高钾均与死亡或肾脏替代治疗启动风险增加相关。

核心结论

  • 在4-5期慢性肾脏病患者中观察到血清钾与死亡或肾脏替代治疗启动呈U形关系,风险最低点在血钾4.9mmol/L,提示预防高钾和低钾均可能重要。

研究设计与样本

  • 前瞻性观察性队列研究,纳入欧洲EQUAL研究中1714例65岁及以上患者,从首次估算肾小球滤过率低于20mL/min/1.73m2测量起随访8年。

主要发现

  • 基线时66%为男性,42%有糖尿病,47%有心血管疾病,54%使用肾素-血管紧张素-醛固酮系统抑制剂,平均年龄76±7岁,平均估算肾小球滤过率17±5mL/min/1.73m2,平均主观全面评估6.0±1.0。
  • 8年随访期间,414例(24%)在启动肾脏替代治疗前死亡,595例(35%)启动肾脏替代治疗。
  • 以血钾>4.0-≤4.5mmol/L为参照,死亡或肾脏替代治疗的校正风险比分别为:≤3.5为1.6(95%CI 1.1-2.3),>3.5-≤4.0为1.4(95%CI 1.1-1.7),>4.5-≤5.0为1.1(95%CI 0.9-1.4),>5.0-≤5.5为1.8(95%CI 1.4-2.3),>5.5-≤6.0为2.2(95%CI 1.5-3.3)。
  • 风险比在血钾约4.9mmol/L处最低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 钾测量间隔较短本可允许更精确的估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Hypokalemia may accelerate kidney function decline. Both hypo- and hyperkalemia can cause sudden cardiac death. However, little is known about the relationship between serum potassium and death or the occurrence of kidney failure requiring replacement therapy (KRT). We investigated this relationship in older people with chronic kidney disease (CKD) stage 4-5. STUDY DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: We followed 1,714 patients (≥65 years old) from the European Quality (EQUAL) study for 8 years from their first estimated glomerular filtration rate (eGFR)<20mL/min/1.73m2 measurement. EXPOSURE: Serum potassium was measured every 3 to 6 months and categorized as≤3.5,>3.5-≤4.0,>4.0-≤4.5,>4.5-≤5.0 (reference),>5.0-≤5.5, >5.5-≤6.0, and>6.0mmol/L. OUTCOME: The combined outcome death before KRT or start of KRT. ANALYTICAL APPROACH: The association between categorical and continuous time-varying potassium and death or KRT start was examined using Cox proportional hazards and restricted cubic spline analyses, adjusted for age, sex, diabetes, cardiovascular disease, renin-angiotensin-aldosterone system (RAAS) inhibition, eGFR, and subjective global assessment (SGA). RESULTS: At baseline, 66% of participants were men, 42% had diabetes, 47% cardiovascular disease, and 54% used RAAS inhibitors. Their mean age was 76±7 (SD) years, mean eGFR was 17±5 (SD) mL/min/1.73m2, and mean SGA was 6.0±1.0 (SD). Over 8 years, 414 (24%) died before starting KRT, and 595 (35%) started KRT. Adjusted hazard ratios for death or KRT according to the potassium categories were 1.6 (95% CI, 1.1-2.3), 1.4 (95% CI, 1.1-1.7), 1.1 (95% CI, 1.0-1.4), 1 (reference), 1.1 (95% CI, 0.9-1.4), 1.8 (95% CI, 1.4-2.3), and 2.2 (95% CI, 1.5-3.3). Hazard ratios were lowest at a potassium of about 4.9mmol/L. LIMITATIONS: Shorter intervals between potassium measurements would have allowed for more precise estimations. CONCLUSIONS: We observed a U-shaped relationship between serum potassium and death or KRT start among patients with incident CKD 4-5, with a nadir risk at a potassium level of 4.9mmol/L. These findings underscore the potential importance of preventing both high and low potassium in patients with CKD 4-5. PLAIN-LANGUAGE SUMMARY: Abnormal potassium blood levels may increase the risk of death or kidney function decline, especially in older people with chronic kidney disease (CKD). We studied 1,714 patients aged≥65 years with advanced CKD from the European Quality (EQUAL) study and followed them for 8 years. We found that both low and high levels of potassium were associated with an increased risk of death or start of kidney replacement therapy, with the lowest risk observed at a potassium level of 4.9 mmol/L. In patients with CKD, the focus is often on preventing high blood potassium. However, this relatively high optimum potassium level stresses the potential importance of also preventing low potassium levels in older patients with advanced CKD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. de Rooij ENM, de Fijter JW, Le Cessie S, et al. Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up. Am J Kidney Dis. 2023. PMID: 37182596. doi:10.1053/j.ajkd.2023.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。